NO307499B1 - Vaksineformulering omfattende Herpes simplex (HSV) glykoprotein gD og 3 deacetylert monofosforyllipid A, anvendelse av HSV glykoprotein gD og fremgangsmÕte for fremstilling av vaksine - Google Patents

Vaksineformulering omfattende Herpes simplex (HSV) glykoprotein gD og 3 deacetylert monofosforyllipid A, anvendelse av HSV glykoprotein gD og fremgangsmÕte for fremstilling av vaksine

Info

Publication number
NO307499B1
NO307499B1 NO933343A NO933343A NO307499B1 NO 307499 B1 NO307499 B1 NO 307499B1 NO 933343 A NO933343 A NO 933343A NO 933343 A NO933343 A NO 933343A NO 307499 B1 NO307499 B1 NO 307499B1
Authority
NO
Norway
Prior art keywords
hsv
glycoprotein
vaccine
preparation
herpes simplex
Prior art date
Application number
NO933343A
Other languages
English (en)
Norwegian (no)
Other versions
NO933343D0 (no
NO933343L (no
Inventor
Myriam Francotte
Jean-Paul Prieels
Moncef Mohamed Slaoui
Nathalie Marie- Garcon-Johnson
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO307499(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of NO933343D0 publication Critical patent/NO933343D0/no
Publication of NO933343L publication Critical patent/NO933343L/no
Publication of NO307499B1 publication Critical patent/NO307499B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
NO933343A 1991-03-21 1993-09-20 Vaksineformulering omfattende Herpes simplex (HSV) glykoprotein gD og 3 deacetylert monofosforyllipid A, anvendelse av HSV glykoprotein gD og fremgangsmÕte for fremstilling av vaksine NO307499B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9105992A GB9105992D0 (en) 1991-03-21 1991-03-21 Vaccine
PCT/EP1992/000592 WO1992016231A1 (en) 1991-03-21 1992-03-17 HERPES SIMPLEX VACCINE COMPRISING HSV GLYCOPROTEIN gD AND 3 dEACYLATED MONOPHOSPHORYL LIPID A

Publications (3)

Publication Number Publication Date
NO933343D0 NO933343D0 (no) 1993-09-20
NO933343L NO933343L (no) 1993-09-20
NO307499B1 true NO307499B1 (no) 2000-04-17

Family

ID=10691946

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933343A NO307499B1 (no) 1991-03-21 1993-09-20 Vaksineformulering omfattende Herpes simplex (HSV) glykoprotein gD og 3 deacetylert monofosforyllipid A, anvendelse av HSV glykoprotein gD og fremgangsmÕte for fremstilling av vaksine

Country Status (34)

Country Link
US (1) US6027730A (ar)
EP (1) EP0576478B2 (ar)
JP (1) JP3530526B2 (ar)
KR (1) KR100224329B1 (ar)
CN (2) CN1058191C (ar)
AP (1) AP298A (ar)
AT (1) ATE129160T1 (ar)
AU (1) AU650521B2 (ar)
BR (1) BR9205745A (ar)
CA (1) CA2106492C (ar)
CY (1) CY1936A (ar)
CZ (1) CZ280505B6 (ar)
DE (1) DE69205566T3 (ar)
DK (1) DK0576478T4 (ar)
ES (1) ES2081102T5 (ar)
FI (1) FI107881B (ar)
GB (1) GB9105992D0 (ar)
GR (1) GR3017884T3 (ar)
HK (1) HK1004525A1 (ar)
HU (1) HU218025B (ar)
IE (1) IE69560B1 (ar)
IL (1) IL101290A (ar)
MA (1) MA22471A1 (ar)
MX (1) MX9201245A (ar)
MY (1) MY110086A (ar)
NO (1) NO307499B1 (ar)
NZ (1) NZ242057A (ar)
PL (1) PL170059B1 (ar)
PT (1) PT100262B (ar)
SA (1) SA92120459B1 (ar)
SK (1) SK279190B6 (ar)
WO (1) WO1992016231A1 (ar)
YU (1) YU28392A (ar)
ZA (1) ZA922011B (ar)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DK0812593T4 (da) * 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
CA2163550A1 (en) * 1993-05-25 1994-12-08 Gerald E. Hancock Adjuvants for vaccines against respiratory syncytial virus
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996020219A2 (en) * 1994-12-28 1996-07-04 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
ATE357252T1 (de) 1998-10-16 2007-04-15 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1104767A1 (en) 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
ES2472441T3 (es) 2004-09-22 2014-07-01 Glaxosmithkline Biologicals S.A. Composición inmunog�nica para uso en vacunación contra estafilococos
PT1861120T (pt) 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
AR058707A1 (es) 2005-12-22 2008-02-20 Glaxosmithkline Biolog Sa Vacuna, procedimiento para fabricarla y su uso
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2486938T3 (pl) 2006-09-26 2018-08-31 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
ES2606563T3 (es) 2009-06-05 2017-03-24 Infectious Disease Research Institute Adyuvantes lipídicos de glucopiranosilo sintéticos y composiciones de vacuna que contienen los mismos
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
PT2516629T (pt) 2009-12-21 2016-07-07 The Brigham And Women`S Hospital Inc Vacinas de vírus herpes simplex
US9782474B2 (en) 2010-11-24 2017-10-10 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN103619350A (zh) * 2011-03-11 2014-03-05 麦克马斯特大学 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
EP2694099B1 (en) 2011-04-08 2019-10-16 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP3329936A1 (en) 2011-08-22 2018-06-06 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
AU2014203873A1 (en) 2013-01-07 2015-07-30 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
US11390650B2 (en) 2018-02-05 2022-07-19 The Brigham And Women's Hospital, Inc. Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) * 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO1988002634A1 (en) * 1986-10-20 1988-04-21 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
AU4525589A (en) * 1988-10-27 1990-05-14 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
US5597573A (en) * 1989-05-04 1997-01-28 Igen, Inc. Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
EP0482068A1 (en) * 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
DE69131984T2 (de) * 1990-08-01 2000-07-06 Res Corp Technologies Inc Das für das pferde herpes-virus typ 1 glykoprotein d, kodierende gen, sein genprodukt, antikörper und ihre verwendung
JP3005292B2 (ja) * 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのｖｐ１６のワクチン
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5196452A (en) * 1991-01-29 1993-03-23 Genelabs Incorporated Macrocyclic anti-viral compound and method
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
KR100278157B1 (ko) * 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DK0812593T4 (da) * 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
CA2163550A1 (en) * 1993-05-25 1994-12-08 Gerald E. Hancock Adjuvants for vaccines against respiratory syncytial virus

Also Published As

Publication number Publication date
IE69560B1 (en) 1996-10-02
JPH06505727A (ja) 1994-06-30
AP298A (en) 1994-01-14
AU1365792A (en) 1992-10-21
CA2106492C (en) 2003-12-09
EP0576478A1 (en) 1994-01-05
CZ280505B6 (cs) 1996-02-14
GB9105992D0 (en) 1991-05-08
MA22471A1 (fr) 1992-10-01
CN1058191C (zh) 2000-11-08
WO1992016231A1 (en) 1992-10-01
SK94693A3 (en) 1994-05-11
MX9201245A (es) 1992-10-01
US6027730A (en) 2000-02-22
FI934134A0 (fi) 1993-09-21
DK0576478T3 (da) 1995-12-04
AP9200368A0 (en) 1992-04-30
EP0576478B2 (en) 2001-04-18
HUT67052A (en) 1995-01-30
HK1004525A1 (en) 1998-11-27
MY110086A (en) 1997-12-31
IE920881A1 (en) 1992-09-23
ATE129160T1 (de) 1995-11-15
CN1065997A (zh) 1992-11-11
PT100262B (pt) 2001-05-31
CA2106492A1 (en) 1992-09-22
GR3017884T3 (en) 1996-01-31
DE69205566T2 (de) 1996-04-18
FI107881B (fi) 2001-10-31
ZA922011B (en) 1993-01-27
DE69205566T3 (de) 2002-09-05
IL101290A0 (en) 1992-11-15
EP0576478B1 (en) 1995-10-18
SK279190B6 (sk) 1998-07-08
KR100224329B1 (ko) 1999-10-15
JP3530526B2 (ja) 2004-05-24
ES2081102T3 (es) 1996-02-16
SA92120459B1 (ar) 2005-06-14
ES2081102T5 (es) 2001-09-01
NZ242057A (en) 1993-12-23
HU218025B (hu) 2000-05-28
CZ195893A3 (en) 1994-07-13
IL101290A (en) 1996-07-23
CY1936A (en) 1992-03-17
YU28392A (sh) 1994-11-15
PT100262A (pt) 1993-06-30
NO933343D0 (no) 1993-09-20
NO933343L (no) 1993-09-20
PL170059B1 (pl) 1996-10-31
BR9205745A (pt) 1994-10-18
CN1201692A (zh) 1998-12-16
CN1101226C (zh) 2003-02-12
AU650521B2 (en) 1994-06-23
DE69205566D1 (en) 1995-11-23
FI934134A (fi) 1993-09-21
DK0576478T4 (da) 2001-07-23
HU9302645D0 (en) 1994-01-28

Similar Documents

Publication Publication Date Title
NO307499B1 (no) Vaksineformulering omfattende Herpes simplex (HSV) glykoprotein gD og 3 deacetylert monofosforyllipid A, anvendelse av HSV glykoprotein gD og fremgangsmÕte for fremstilling av vaksine
DK0689454T4 (da) Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
HU9303282D0 (en) Pharmaceutical preparations containing hialuronic acid and/or derivatives and/or fragments
MX17752A (es) Formulaciones farmaceuticas y procedimiento para prepararlas
HU9303283D0 (en) Pharmaceutical preparations containing hialuronic acid and/or derivatives and/or fragments
DE3275904D1 (en) Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
FI94591B (fi) Menetelmä antiviraalisten ja immunostimuloivien farmaseuttisten koostumusten valmistamiseksi
IL99851A0 (en) Muramyldipeptide derivatives and influenza vaccine containing them
AU1631188A (en) Newcastle disease virus vaccine and method for the application thereof
PT87776A (pt) Aminocyclopentyl ethers and their preparation and pharmaceutical formulation
AU5252090A (en) Improvements in and relating to pharmaceutical formulations
AU3614493A (en) Non-toxic lipid vaccine formulations
AU586299B2 (en) Vaccine against mumps and process for its preparation
AU625163B2 (en) Dihydrocaffeic acid derivatives and pharmaceutical preparations containing same
AU2971692A (en) Flystrike antigen and vaccine and method for preparation
ZA871323B (en) Purified human angiogenic factor,method for its preparation and pharmaceutical preparations
IL102290A0 (en) Ccv vaccine and its preparation
AU3565289A (en) Immunogenic complex and its use in vaccination
EP0268389A3 (en) Cyclopenthyl ethers and their preparation and pharmaceutical formulation
SG168394G (en) Method and formulation for orally administering bioactive agents to and through the peyer's patch
RO101947B1 (en) Marek's disease vaccine and preparation method
GR862115B (en) Vaccine and preparation method thereof
IT8819665A0 (it) (1,2_di_0_acetil_glicero_3_fosforil)_colina, procedimento per la sua preparazione e suo uso terapeutico.
IT8819669A0 (it) 2_0_acetil_1,3bis(difosforil_colina)_glicerolo procedimento per la sua preparazione e suo uso terapeutico.
BR9501254A (pt) Formulaçao para administraçao oral e processo para sua preparaçao

Legal Events

Date Code Title Description
MK1K Patent expired